The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors
Healthcare >> CEO Interviews >> August 12, 2016

Interview with the President and CEO: Mateon Therapeutics, Inc. (NASDAQ:MATN)

Schwieterman, William D.
William D. Schwieterman, M.D., is President and Chief Executive Officer of Mateon Therapeutics, Inc. Dr. Schwieterman has assembled a world-class management team and is working to transform the organization into a leading oncology company. Dr. Schwieterman is a rheumatologist and board-certified internist with more than 15 years of executive, regulatory and drug development experience in the biopharmaceutical industry. He has been an independent consultant to multiple biotech and pharmaceutical clients where he helped them create their regulatory and clinical development strategies. Before joining Mateon, he was an employee of Perceptive Advisors, LLC, a hedge fund based in New York, New York. Dr. Schwieterman was also the Chief Medical Officer of Chelsea Therapeutics, Inc., a publicly traded biopharmaceutical development company, where he led the clinical development team toward the approval of droxidopa — Northera — for the treatment of symptomatic neurogenic orthostatic hypotension, a nonmotor symptom, associated with Parkinson’s disease and other neurogenerative diseases. Dr. Schwieterman was formerly Chief of the Medicine Branch and Chief of the Immunology and Infectious Disease Branch in the Division of Clinical Trials at the Food and Drug Administration, or FDA. In these capacities and others, Dr. Schwieterman spent 10 years at the FDA in the Center for Biologics overseeing a wide range of clinical development plans for a large number of different types of molecules. Dr. Schwieterman holds a B.S. and M.D. from the University of Cincinnati. Profile
TWST: Mateon Therapeutics was once known as OXiGENE. Can you talk about the transition to the new company name, the branding and what the company is doing?

Dr.

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Walmart Inc.
International Business Machines Corporation
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc
CEO INTERVIEWS
Interview with the CEO: BetterLife Pharma Inc. (OTCMKTS:BETRF)
Interview with the CEO: Cansortium Inc. (OTCMKTS:CNTMF)
Interview with the Co-CEO and the CAO: Planet 13 Holdings Inc. (OTCMKTS:PLNH)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
Profitability Strategy Pays Off for Bank IT Company Q2 Holdings
Three Mid-Cap Names Using Their Balance Sheets to Create Value
Look Beyond Traditional Emerging Markets for More Diversification, Less Risk
ANALYST INTERVIEWS
Five Companies Dominate in Psychedelics-Based Drug Development
Cidara’s Long-Acting Antiviral Drug Could Be a Game Changer
Spotting Potential in the High-Risk, High Reward Neuroscience Space
Since 1963
© The Wall Street Transcript 2016, 2024
Terms and Conditions
Privacy Policy